Bioatla Share Price Today
(NASDAQ: BCAB)

Name: Bioatla Share Price Today (NASDAQ: BCAB) - Bioatla Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Bioatla share price is $0.35 & ₹30.44 as on 6 Mar 2025, 2.30 'hrs' IST

$0.35

▲

0.03

(9.72%)

Market is closed - opens 8 PM, 06 Mar 2025

View live Bioatla share price in Dollar and Rupees. Guide to invest in Bioatla stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Bioatla, along with analyst recommendations, forecasts, and comprehensive financials.

Bioatla share price movements

Today's Low: $0.31
Today's High: $0.35
$0.35
11.43%
Downside
Day's Volatility :11.55%
Upside
0.14%
52 Weeks Low: $0.28
52 Weeks High: $4.02
$0.35
19.83%
Downside
52 Weeks Volatility :93.02%
Upside
91.29%

Bioatla (BCAB) Returns

Period	Bioatla Inc	Sector (Health Care)	Index (Russel 2000)
3 Months	-79.55%	2.1%	0.0%
6 Months	-82.76%	-4.1%	0.0%
1 Year	-88.77%	2.2%	0.0%
3 Years	-94.11%	11.8%	-11.6%

Bioatla (BCAB) Key Statistics

in dollars & INR

Previous Close	$0.319
Open	$0.3266
Today's High	$0.3505
Today's Low	$0.31
Market Capitalization	$17.7M
Today's Volume	$374.0K
52 Week High	$4.02
52 Week Low	$0.2806
Revenue TTM	$11.0M
EBITDA	$-85.2M
Earnings Per Share (EPS)	$-1.7
Profit Margin	0.0%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-139.06%

How to invest in Bioatla Stock (BCAB) from India?

It is very easy for Indian residents to invest directly in Bioatla from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Bioatla stock in both Indian Rupees (INR) and US Dollars (USD). Search for Bioatla or BCAB on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Bioatla or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Bioatla shares which would translate to 2.485 fractional shares of Bioatla as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Bioatla, in just a few clicks!

Returns in Bioatla (BCAB) for Indian investors in Rupees

The Bioatla stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

Bioatla investment value today

Current value as on today

₹17,287

Returns

₹82,713

(-82.71%)

Returns from Bioatla Stock

₹87,676 (-87.68%)

Dollar Returns

₹4,963 (+4.96%)

Indian investors sentiment towards Bioatla (BCAB)

-3%

Period: Feb 3, 2025 to Mar 5, 2025. Change in 30 Days versus previous period

Search interest for Bioatla Stock from India on INDmoney has decreased by -3% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Bioatla

Anson Funds Management LP
7.93%
Highbridge Capital Management, LLC
4.33%
Vanguard Group Inc
3.16%
TANG CAPITAL MANAGEMENT LLC
2.37%
Morgan Stanley - Brokerage Accounts
1.90%
Millennium Management LLC
1.89%

Analyst Recommendation on Bioatla

Buy

90%Buy

9%Hold

0%Sell

Based on 11 Wall street analysts offering stock ratings for Bioatla(by analysts ranked 0 to 5 stars)

Based on 11 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Bioatla Stock (BCAB)

What analysts predicted

Upside of 2471.43%

Target:

$9.00

Current:

$0.35

Insights on Bioatla Stock (Ticker Symbol: BCAB)

Price Movement
In the last 1 month, BCAB stock has moved down by -35.7%
BCAB vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 62.3% return, outperforming this stock by 150.8%
BCAB vs VRTX (3 yr)
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 47.7% return, outperforming this stock by 141.9%
Price to Sales
ForBCAB every $1 of sales, investors are willing to pay $1.4, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $13.8 for every $1 of sales.

Bioatla Technicals Summary

Sell

Neutral

Buy

Bioatla is currently in a neutral trading position according to technical analysis indicators.

Bioatla (BCAB) Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Bioatla Inc	-29.75%	-82.76%	-88.77%	-94.11%	-98.97%
Regeneron Pharmaceuticals, Inc.	1.3%	-41.29%	-30.51%	9.2%	42.38%
Beone Medicines Ltd	15.19%	34.31%	61.3%	43.16%	68.1%
Vertex Pharmaceuticals Incorporated	3.37%	3.77%	18.06%	106.43%	121.36%
Alnylam Pharmaceuticals, Inc.	-11.52%	-3.4%	62.32%	49.04%	120.93%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Bioatla Inc	NA	NA	NA	-1.52	-1.39	-0.5	NA	0.48
Regeneron Pharmaceuticals, Inc.	17.85	17.85	1.03	43.09	0.16	0.07	0.01	273.57
Beone Medicines Ltd	NA	NA	NA	1.43	-0.19	-0.06	NA	31.22
Vertex Pharmaceuticals Incorporated	32.84	NA	1.33	18.07	-0.03	0.13	NA	63.87
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	0.57	-15.01	-0.03	NA	0.52

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Bioatla Inc	Buy	$17.7M	-98.97%	NA	0.0%
Regeneron Pharmaceuticals, Inc.	Buy	$74.9B	42.38%	17.85	31.07%
Beone Medicines Ltd	NA	$28.5B	68.1%	NA	-16.92%
Vertex Pharmaceuticals Incorporated	Buy	$124.1B	121.36%	32.84	-4.86%
Alnylam Pharmaceuticals, Inc.	Buy	$31.5B	120.93%	NA	-12.37%

About Bioatla

BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody, which is in Phase II clinical trial for treating melanoma, carcinomas, and NSCLC; and BA3182, a bispecific candidate that is in Phase 1 study for the treatment of adenocarcinomas, as well as BA3361, which is in preclinical studies for treating multiple tumor types. The company was founded in 2007 and is headquartered in San Diego, California.

Organization	Bioatla
Employees	65
CEO	Dr. Jay M. Short Ph.D.
Industry	Healthcare

Management People of Bioatla

Name	Title
Dr. Jay M. Short Ph.D.	Co-Founder, CEO & Chairman
Mr. Richard A. Waldron	Senior VP & CFO
Dr. Eric L. Sievers M.D.	Chief Medical Officer
Mr. Christian J. Vasquez CPA	Chief Accounting Officer, Controller and Corporate Secretary
Ms. Susie Melody	Senior Vice President of Human Resources
Dr. Cathy Chang Ph.D.	Senior Vice President of Research & Development
Dr. Gerhard Frey Ph.D.	Senior Vice President of Technology Development
Ms. Monica Sullivan	Senior Vice President of Intellectual Property & Contracts
Ms. Sheri Lydick	Chief Commercial Officer
Lisa M. Pelton	Accounting Manager

Important FAQs about investing in BCAB Stock from India :

What is Bioatla share price today?

Bioatla share price today stands at $0.35, Open: $0.33 ; Previous Close: $0.32 ; High: $0.35 ; Low: $0.31 ; 52 Week High: $4.02 ; 52 Week Low: $0.28.

The stock opens at $0.33, after a previous close of $0.32. The stock reached a daily high of $0.35 and a low of $0.31, with a 52-week high of $4.02 and a 52-week low of $0.28.

Can Indians buy Bioatla shares?

Yes, Indians can invest in the Bioatla (BCAB) from India.

With INDmoney, you can buy Bioatla at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Bioatla at zero transaction cost.

How can I buy Bioatla shares from India?

It is very easy to buy Bioatla from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Bioatla (BCAB) be purchased?

Yes, you can buy fractional shares of Bioatla with INDmoney app.

What are the documents required to start investing in Bioatla stocks?

To start investing in Bioatla, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.